Showing results (141-150 of 163) with videos related to

Sort By:
Pageof 17
Hepatology (Baltimore, Md.)|March 16, 2017
Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinomaYingyun Yang, Ye Zhou, Jin Hou, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2021
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trialYe Guo, Yi Luo, Qingyuan Zhang, et al.
The Oncologist|January 25, 2014
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinomaJifang Gong, Bing Hu, Xiaotian Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2019
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II TrialJianming Xu, Jie Li, Chunmei Bai, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)Jiarui Li, Yuejuan Cheng, Chunmei Bai, et al.
The Oncologist|April 21, 2022
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and BiomarkersYakun Wang, Tianshu Liu, Gongyan Chen, et al.
International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Journal of Gastrointestinal Oncology|September 12, 2022
Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)Xiang Wang, Diansheng Zhong, Junping Zhang, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Chunmei Bai, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 16, 2023
Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinibJianwei Zhang, Haibin Zhu, Lin Shen, et al.
Pageof 17